Ivana Samaržija

Rudjer Boskovic Institute — Croatia

Biochemistry, Genetics and Molecular Biology · Life Sciences

16h-index1.2kcitations55works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Angiogenesis and VEGF in Cancer(13), Epigenetics and DNA Methylation(11), Vascular Tumors and Angiosarcomas(11), Cell Adhesion Molecules Research(8), Cancer-related gene regulation(8)

Publications55 total

Proteoglycans in Prostate Cancer Progression and Therapy Resistance
Medicina·2025Open Access
The extracellular matrix component perlecan/HSPG2 regulates radioresistance in prostate cancer cells
Frontiers in Cell and Developmental Biology·2024· 4 citedOpen Access
The Potential of Extracellular Matrix- and Integrin Adhesion Complex-Related Molecules for Prostate Cancer Biomarker Discovery
Biomedicines·2023· 12 citedOpen Access
Extracellular Matrix- and Integrin Adhesion Complexes-Related Genes in the Prognosis of Prostate Cancer Patients’ Progression-Free Survival
Biomedicines·2023· 5 citedOpen Access
Supplementary Methods and Materials, Figure Legends 1-4 from Inhibition of Multiple Vascular Endothelial Growth Factor Receptors (VEGFR) Blocks Lymph Node Metastases but Inhibition of VEGFR-2 Is Sufficient to Sensitize Tumor Cells to Platinum-Based Chemotherapeutics
2023Open Access
Supplementary Figure 4 from Inhibition of Multiple Vascular Endothelial Growth Factor Receptors (VEGFR) Blocks Lymph Node Metastases but Inhibition of VEGFR-2 Is Sufficient to Sensitize Tumor Cells to Platinum-Based Chemotherapeutics
2023Open Access
Data from Inhibition of Multiple Vascular Endothelial Growth Factor Receptors (VEGFR) Blocks Lymph Node Metastases but Inhibition of VEGFR-2 Is Sufficient to Sensitize Tumor Cells to Platinum-Based Chemotherapeutics
2023Open Access
Supplementary Figure 4 from Inhibition of Multiple Vascular Endothelial Growth Factor Receptors (VEGFR) Blocks Lymph Node Metastases but Inhibition of VEGFR-2 Is Sufficient to Sensitize Tumor Cells to Platinum-Based Chemotherapeutics
2023Open Access
Supplementary Figure 1 from Inhibition of Multiple Vascular Endothelial Growth Factor Receptors (VEGFR) Blocks Lymph Node Metastases but Inhibition of VEGFR-2 Is Sufficient to Sensitize Tumor Cells to Platinum-Based Chemotherapeutics
2023Open Access
Supplementary Methods and Materials, Figure Legends 1-4 from Inhibition of Multiple Vascular Endothelial Growth Factor Receptors (VEGFR) Blocks Lymph Node Metastases but Inhibition of VEGFR-2 Is Sufficient to Sensitize Tumor Cells to Platinum-Based Chemotherapeutics
2023Open Access
Supplementary Figure 3 from Inhibition of Multiple Vascular Endothelial Growth Factor Receptors (VEGFR) Blocks Lymph Node Metastases but Inhibition of VEGFR-2 Is Sufficient to Sensitize Tumor Cells to Platinum-Based Chemotherapeutics
2023Open Access
Supplementary Figure 2 from Inhibition of Multiple Vascular Endothelial Growth Factor Receptors (VEGFR) Blocks Lymph Node Metastases but Inhibition of VEGFR-2 Is Sufficient to Sensitize Tumor Cells to Platinum-Based Chemotherapeutics
2023Open Access
Supplementary Figure 2 from Inhibition of Multiple Vascular Endothelial Growth Factor Receptors (VEGFR) Blocks Lymph Node Metastases but Inhibition of VEGFR-2 Is Sufficient to Sensitize Tumor Cells to Platinum-Based Chemotherapeutics
2023Open Access
Data from Inhibition of Multiple Vascular Endothelial Growth Factor Receptors (VEGFR) Blocks Lymph Node Metastases but Inhibition of VEGFR-2 Is Sufficient to Sensitize Tumor Cells to Platinum-Based Chemotherapeutics
2023Open Access
Supplementary Figure 3 from Inhibition of Multiple Vascular Endothelial Growth Factor Receptors (VEGFR) Blocks Lymph Node Metastases but Inhibition of VEGFR-2 Is Sufficient to Sensitize Tumor Cells to Platinum-Based Chemotherapeutics
2023Open Access
Supplementary Figure 1 from Inhibition of Multiple Vascular Endothelial Growth Factor Receptors (VEGFR) Blocks Lymph Node Metastases but Inhibition of VEGFR-2 Is Sufficient to Sensitize Tumor Cells to Platinum-Based Chemotherapeutics
2023Open Access
Prognostic Significance of Amino Acid Metabolism-Related Genes in Prostate Cancer Retrieved by Machine Learning
Cancers·2023· 12 citedOpen Access
Genome-Wide Methylation Profiling in 229 Patients With Crohn’s Disease Requiring Intestinal Resection: Epigenetic Analysis of the Trial of Prevention of Post-operative Crohn’s Disease (TOPPIC)
Cellular and Molecular Gastroenterology and Hepatology·2023· 15 citedOpen Access
EZH2 Inhibition and Cisplatin as a Combination Anticancer Therapy: An Overview of Preclinical Studies
Cancers·2022· 37 citedOpen Access
A need for stratification of metastasis samples according to secondary site in gene expression studies
Biocell·2022· 1 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Nancy E. Hynes(12), Vlatka Zoldoš(11), Aleksandar Vojta(11), Patrizia Sini(11), Fabienne Baffert(11), Amanda Littlewood‐Evans(11), Christian Schnell(11), Andreas Theuer(11), Sven Christian(11), Anja M. Boos(11), Holger Hess‐Stumpp(11), John A. Foekens(11), Buddy Setyono-Han(11), Jeanette M. Wood(11), Dora Markulin(9), Andreja Ambriović‐Ristov(7), Gordan Lauc(6), Jonathan D. Humphries(6), Nikolina Stojanović(6), Martin J. Humphries(6)